๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery โ—† GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons โ—† Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing โ—† Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines โ—† Trumpโ€™s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery โ—† GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons โ—† Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing โ—† Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines โ—† Trumpโ€™s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications โ—†
Updated 04 Jul 2026 ยท HPRA open data

Efavirenz - Medicines in Ireland

14 authorised products containing Efavirenz, from the HPRA register.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0โ€“9
Showing 14 authorised medicines
MedicineActive substanceLicence holderStatus
Efavirenz Teva 600 mg film-coated tablets
EU/1/11/742/001-010
Efavirenz Teva B.V. โ€”
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg film-coated tablets
EU/1/17/1263/001-002
Tenofovir disoproxil succinate, Efavirenz, Emtricitabine KRKA, d.d., Novo mesto โ€”
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan 600 mg/200 mg/245 mg film-coated tablets
EU/1/17/1222/001-002
Efavirenz, Tenofovir disoproxil maleate, Emtricitabine Mylan Pharmaceuticals Limited โ€”
Efavirenz/Emtricitabine/Tenofovir disoproxil Teva 600 mg/200 mg/245 mg Film-coated Tablets
PA1986/033/001
Efavirenz, Emtricitabine, Tenofovir disoproxil Teva B.V. Marketed
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva 600 mg/200 mg/245 mg film-coated tablets
EU/1/17/1210/001
Tenofovir disoproxil phosphate, Efavirenz, Emtricitabine Zentiva k.s. โ€”
Stocrin
EU/1/99/111/003
Efavirenz Merck Sharp & Dohme BV, โ€”
Stocrin
EU/1/99/111/004
Efavirenz Merck Sharp & Dohme BV, โ€”
STOCRIN
EU/1/99/111/001
Efavirenz Merck Sharp & Dohme BV, โ€”
STOCRIN
EU/1/99/111/002
Efavirenz Merck Sharp & Dohme BV, โ€”
STOCRIN 200 mg film-coated tablets
EU/1/99/111/011
Efavirenz Merck Sharp & Dohme BV, โ€”
STOCRIN 30 mg/mL oral solution
EU/1/99/111/005
Efavirenz Merck Sharp & Dohme BV, โ€”
STOCRIN 50 mg film-coated tablets
EU/1/99/111/010
Efavirenz Merck Sharp & Dohme BV, โ€”
Stocrin Film-Coated
EU/1/99/111/6-7
Efavirenz Merck Sharp & Dohme BV, โ€”
Stocrin Film-Coated
EU/1/99/111/8-9
Efavirenz Merck Sharp & Dohme BV, โ€”
Cite this database

Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 15 August 2026).

Data: Health Products Regulatory Authority (HPRA) open dataset (โ€œAuthorised or Transfer Pending Productsโ€), licensed CC BY 4.0, refreshed daily. Regulatory information only โ€” not medical advice.